You're hearing about gene therapy. Maybe your child's neurologist mentioned it at the last appointment. Maybe another parent brought it up in a support group. Maybe you saw a headline and wondered if this changes everything for your family.

Here's what's real in 2026: ELEVIDYS, the first FDA-approved gene therapy for Duchenne muscular dystrophy, now has expanded approval. More boys qualify. RGX-202 is in the pipeline and expected around 2027. These are genuine advances, the biggest developments in DMD treatment in decades. They're also expensive, eligibility-restricted, and still unfolding in terms of long-term outcomes.

And while gene therapy is making headlines, respiratory care milestones, positioning routines, cardiac monitoring, and school accommodations still define daily life for most families. This guide covers both: how to evaluate gene therapy as an option, and how to manage the realities that persist regardless of which treatments your child receives.

ELEVIDYS: What It Is and Who Qualifies

ELEVIDYS (delandistrogene moxeparvovec) is a one-time gene therapy approved for boys with Duchenne muscular dystrophy. It delivers a modified version of the dystrophin gene (the protein boys with DMD can't produce on their own) using a viral vector.

The original approval in 2023 was narrow: boys ages 4 to 5 with confirmed DMD mutations. In 2025, the FDA expanded approval to include boys ages 4 to 7 who are still ambulatory. That means more families now have access, but the eligibility window is still tight.

Your child may qualify if:

• He has a confirmed DMD genetic mutation (through genetic testing, not just clinical diagnosis)
• He's between 4 and 7 years old
• He's still walking independently or with minimal assistance
• He doesn't have pre-existing immunity to the AAV9 viral vector (a blood test checks this)

If your child is older, already using a wheelchair full-time, or has certain immune markers, ELEVIDYS isn't currently an option. That doesn't mean nothing else is. Corticosteroids, physical therapy, respiratory support, and cardiac monitoring all extend quality of life and function. But gene therapy eligibility is time-limited and mutation-specific.

The Cost and Insurance Reality

ELEVIDYS costs approximately $3.2 million for the one-time infusion. That number stops most parents cold.

Insurance coverage is inconsistent. Some commercial plans cover it as an FDA-approved treatment. Some require prior authorization that takes months. Medicaid coverage varies by state: some have carved out pathways for gene therapies, others haven't updated their formularies yet.

If your child qualifies medically but coverage is denied, the manufacturer (Sarepta Therapeutics) has a patient assistance program. You'll need your neurologist to initiate the appeal process and document medical necessity. Denials can be appealed, but the timeline matters. Your child's eligibility window won't wait indefinitely.

Before you start this process, ask your care team:

• Does our insurance typically cover gene therapies?
• How long does prior authorization take at this hospital?
• If we're denied, what's the appeal timeline?
• Is there a social worker or financial navigator who handles these cases?

What to Ask Your Neurologist About Gene Therapy

If you're considering ELEVIDYS, bring these questions to your next appointment:

Eligibility:

• Does my child's specific mutation respond to this therapy?
• What's his current functional status, and does that meet the ambulatory requirement?
• Has he been tested for AAV9 immunity?

Evidence and expectations:

• What does the clinical trial data show about outcomes at 2 years, 5 years?
• What functional improvements can we realistically expect?
• What are the most common side effects, and how are they managed?

Logistics:

• Where would the infusion happen, and how long is the hospital stay?
• What follow-up testing and monitoring is required?
• If we proceed, what's the timeline from decision to infusion?

Trade-offs:

• If we do gene therapy, does it affect eligibility for other treatments down the line?
• If we don't do it now, can we revisit this later?

Gene therapy isn't a cure. It slows progression and may preserve function longer, but it doesn't reverse damage that's already happened, and it doesn't eliminate the need for ongoing care.

RGX-202 and What's Coming Next

RGX-202, developed by Regenxbio, is a second-generation gene therapy currently in Phase III trials. Early data suggests it may work for a broader age range and for boys who are no longer ambulatory. Expected FDA review is late 2027.

If your child doesn't qualify for ELEVIDYS now, RGX-202 might be an option in the next two years. If you're deciding whether to pursue ELEVIDYS now or wait, consider:

• Your child's current rate of progression
• Whether he'll still meet ambulatory criteria in two years
• The risk of waiting versus the potential benefit of a treatment with more data

There's no universal right answer. Some families pursue what's available now. Others wait for more evidence or a broader treatment window. Both are reasonable.

Respiratory Care Milestones That Matter Now

Gene therapy or not, respiratory care is the single most important factor in extending life expectancy for boys with muscular dystrophy. Respiratory muscle weakness is progressive, and monitoring starts early, even when breathing feels normal.

Pulmonary function testing:

Should happen every 6 to 12 months starting around age 5 or 6. This tracks forced vital capacity (FVC), the amount of air your child can forcefully exhale. Once FVC drops below 60% of predicted, respiratory interventions become critical.

BiPAP (bilevel positive airway pressure):

Usually introduced when:

• FVC drops below 50%
• Your child starts experiencing morning headaches (a sign of CO2 retention overnight)
• Sleep quality declines

BiPAP is non-invasive: it's a mask worn at night that assists breathing while your child sleeps. Getting your child comfortable with it early, before it's medically urgent, makes the transition easier.

Cough assist devices:

Help clear mucus when cough strength weakens. A weak cough means respiratory infections are harder to clear and more likely to become pneumonia. Many families start using a cough assist device during colds or respiratory infections, then transition to daily use as needed.

Ventilator use:

Becomes necessary when BiPAP is no longer sufficient, usually in the teenage years or early adulthood. This can be non-invasive (mask-based) or invasive (tracheostomy), depending on the level of support needed and family goals.

Ask your pulmonologist:

• What's my child's current FVC?
• At what threshold do you recommend BiPAP?
• What does the progression timeline typically look like for his specific type of MD?

Daily Management: Positioning, PT, and Orthotic Use

Physical therapy and positioning routines don't reverse muscle loss, but they prevent secondary complications (contractures and scoliosis) that can make daily life harder.

Stretching and range-of-motion exercises:

Should happen daily, focusing on ankles, knees, hips, and elbows. As muscles weaken, joints tighten. Daily stretching keeps joints mobile and reduces pain.

Orthotics (ankle-foot orthoses, or AFOs):

Help maintain ankle alignment and prevent foot drop. Many boys start wearing AFOs at night around age 4 to 6, then transition to wearing them during the day as walking becomes harder. AFOs don't stop progression, but they do keep the ankle in a functional position longer.

Positioning at night:

Matters more than most families realize. Boys with MD are at risk for scoliosis as back muscles weaken. Sleeping in a neutral spine position, with proper pillow support, can slow the curve. If scoliosis does develop, spinal fusion surgery is often recommended before respiratory function declines too much to tolerate anesthesia safely.

Transfers and mobility aids:

Become part of life as walking becomes harder. Power wheelchairs preserve energy and independence. Lift systems reduce caregiver injury. These are tools that let your child keep participating in school, social life, and family outings, not failures.

Cardiac Monitoring and Why It Starts Early

Cardiomyopathy (weakening of the heart muscle) is common in DMD, usually starting in the early teenage years but sometimes earlier. An echocardiogram every 1 to 2 years tracks heart function before symptoms appear.

ACE inhibitors or beta-blockers are often started as soon as heart function shows early decline, even if your child feels fine. These medications slow progression and reduce the risk of heart failure later.

If your child is on corticosteroids (prednisone or deflazacort), cardiac monitoring is even more important. Steroids have cardiovascular side effects that compound the underlying MD risk.

Ask your cardiologist:

• What's my child's current ejection fraction?
• At what point do you start medication?
• How often should we repeat the echocardiogram?

Nutrition and Feeding Challenges

Weight management is tricky in MD. Early on, many boys gain weight as mobility decreases but appetite stays the same. Later, as swallowing weakens, getting enough calories becomes harder.

Early years:

Focus on portion control and nutrient-dense foods. Excess weight makes mobility harder and increases fall risk. A dietitian familiar with neuromuscular conditions can help.

Swallowing difficulties:

Usually start in the teenage years. Signs include coughing during meals, taking longer to eat, or avoiding certain textures. A swallowing study (modified barium swallow) identifies which textures are safest.

G-tube placement:

May be recommended when swallowing becomes unsafe or when eating enough by mouth requires so much effort that your child loses weight. A G-tube doesn't mean no oral eating. It means safe supplementation so mealtime isn't a battle.

School Accommodations That Work

An IEP or 504 plan should evolve as your child's needs change. Static plans fail kids with progressive conditions.

Early elementary:

• Extra time for transitions between classes
• Access to an elevator
• Classroom seating near the door
• Modified PE or adaptive PE

Upper elementary and middle school:

• Scribe or speech-to-text software for writing assignments
• Access to power wheelchair at school
• Bathroom accommodations (grab bars, accessible stall, extra time)
• Plan for fatigue management (shorter school day, rest breaks)

High school:

• Transportation plan that accommodates wheelchair and medical equipment
• Emergency plan for power outages (if on BiPAP or ventilator)
• Transition planning for post-secondary options

Ask for an IEP meeting any time your child's physical abilities change. Don't wait for the annual review.

What Parents Can Control (and What They Can't)

You can't stop progression. You can monitor it closely and act early when interventions will help. You can't cure MD. You can manage complications before they become crises. You can't give your child a life without medical complexity. You can give him a life where he's known for more than his diagnosis.

Gene therapy is one tool. Respiratory care, PT, cardiac monitoring, and school advocacy are others. Managing both the medical decisions and the daily routines, without guilt about whether you're doing enough, is the work.

FAQ

Can gene therapy cure Duchenne muscular dystrophy?

No. ELEVIDYS is not a cure. It slows disease progression by delivering a modified dystrophin gene, but it doesn't reverse damage that's already occurred. Boys who receive gene therapy still need ongoing respiratory care, physical therapy, and cardiac monitoring.

What happens if my child doesn't qualify for ELEVIDYS?

Corticosteroids (prednisone or deflazacort) remain the standard of care and significantly slow progression. Physical therapy, respiratory support, and cardiac monitoring extend quality of life and function. RGX-202, a second-generation gene therapy, may offer a broader eligibility window when it's approved in the next few years.

How do I know if my child needs BiPAP?

Your pulmonologist will monitor forced vital capacity (FVC) through regular pulmonary function tests. BiPAP is typically recommended when FVC drops below 50%, or when your child starts experiencing morning headaches or poor sleep quality due to CO2 retention overnight.

Does insurance cover gene therapy?

Coverage is inconsistent. Some commercial plans cover ELEVIDYS as an FDA-approved treatment. Medicaid coverage varies by state. If coverage is denied, the manufacturer offers a patient assistance program, and denials can be appealed. Work with your care team's financial navigator to understand your options.

When should we start talking about a wheelchair?

When walking becomes effortful enough that it limits participation. A power wheelchair isn't a failure. It's a tool that preserves energy and independence. Many boys start using a wheelchair part-time (for school, outings) while still walking at home, then transition to full-time use as needed.

How often should my child see a cardiologist?

Every 1 to 2 years, starting around age 8 to 10. Echocardiograms track heart function before symptoms appear. If early decline is detected, medications like ACE inhibitors or beta-blockers are started to slow progression and reduce the risk of heart failure later.